– USA, CA – Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Dr. Eric Dube, Ph.D. to its Board of Directors.
“We are very pleased to announce the addition of Eric Dube to the Reneo Board,” said CEO, Gregory Flesher. “Eric is an accomplished pharmaceutical industry executive and a leader in the rare disease field. We look forward to his guidance and insights as we work to advance REN001 and lead Reneo to its next phase of development.”
About Dr. Eric Dube
Dr. Dube is the President, CEO, and Director of Travere Therapeutics, a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare diseases. Before joining Travere Therapeutics, Dr. Dube was President and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company’s North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube’s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. Dr. Dube currently serves on the Board of Trustees for AIDS United and the Board of Directors for the Biotechnology Innovation Organization and Biocom California. Dr. Dube has previously been named a Fortune magazine “40 Under 40: Ones to Watch” and one of the “Emerging Pharma Leaders” by Pharmaceutical Executive. He has also been named by the Financial Times as one of the “OUTstanding 100 LGBT+ Executives.”
Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Reneo is developing REN001 to modulate genes critical to the metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase the transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase the production of new mitochondria.
For more information: https://reneopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
